Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Eisai R & d Management Co Ltd patents


Recent patent applications related to Eisai R & d Management Co Ltd. Eisai R & d Management Co Ltd is listed as an Agent/Assignee. Note: Eisai R & d Management Co Ltd may have other listings under different names/spellings. We're not affiliated with Eisai R & d Management Co Ltd, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "E" | Eisai R & d Management Co Ltd-related inventors


Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b

The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing... Eisai R & d Management Co Ltd

Pyrimidine fgfr4 inhibitors

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.... Eisai R & d Management Co Ltd

Method for treating cancer

The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).... Eisai R & d Management Co Ltd

Topical formulations of pde-4 inhibitors and their methods of use

Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited... Eisai R & d Management Co Ltd

Cationic lipid

The present invention provides a cationic lipid which can be utilized for nucleic acid delivery into the cytoplasm. The cationic lipid of the present invention is, for example, a compound represented by the following Formula (1) or a pharmaceutically acceptable salt thereof.... Eisai R & d Management Co Ltd

Methods useful in the synthesis of halichondrin b analogs

In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).... Eisai R & d Management Co Ltd

Compositions and methods for treating insomnia

In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.... Eisai R & d Management Co Ltd

Stereochemically defined polypropionates and methods for making and using the same

The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.... Eisai R & d Management Co Ltd

High-purity quinoline derivative and manufacturing same

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.... Eisai R & d Management Co Ltd

Salt of monocyclic pyridine derivative and crystal thereof

and crystals thereat which can be used as bulk materials for pharmaceuticals.... Eisai R & d Management Co Ltd

Method for producing pyrimidine-1-ol compound, and intermediate thereof

There are provided a method for producing 2,4-disubstituted pyrimidine-5-ol, and particularly, 2,4-dimethylpyrimidine-5-ol and an intermediate thereof used in industrial production. The production method according to the present invention includes a step of producing 2,4-disubstituted pyrimidine-5-ol according to a hydrolysis reaction of a 2,4-disubstituted-5-(4-(nitrophenyl)oxy)pyrimidine compound and is suitable for industrial production... Eisai R & d Management Co Ltd

Lyophilized formulation of hgf

The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.... Eisai R & d Management Co Ltd

Method for predicting effectiveness of angiogenesis inhibitor

The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf... Eisai R & d Management Co Ltd

Combination therapies for the treatment of cancer

The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.... Eisai R & d Management Co Ltd

Anti-folate receptor alpha antibodies and uses thereof

Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers,... Eisai R & d Management Co Ltd

Salt form of a human histone methyltransferase ezh2 inhibitor

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.... Eisai R & d Management Co Ltd

Pyranodipyridine compound

Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:... Eisai R & d Management Co Ltd

Use of eribulin in the treatment of cancer

The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.... Eisai R & d Management Co Ltd

Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer

The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP inhibitor... Eisai R & d Management Co Ltd

Anti human notch4 antibody

The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and... Eisai R & d Management Co Ltd

Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer

Methods for treating cancer (e.g., breast cancer, lung cancer, pancreatic cancer, primitive neuroectodermal tumors, lung cancer, ovarian cancer, endometrial cancer, pharyngeal cancer, esophageal cancer, and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e.g., eribulin mesylate, i.e., E7389, Halaven) in combination with one... Eisai R & d Management Co Ltd

Pyrimidine fgfr4 inhibitors

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.... Eisai R & d Management Co Ltd

Revascularization graft material

Provided is a graft material capable of securing a sufficient space for regenerated tissue in the implantation site, and thereby promoting the regeneration of a blood vessel. Specifically, the present invention provides a revascularization graft material including an outer tube and an inner tube each being formed by knitting twisted... Eisai R & d Management Co Ltd








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Eisai R & d Management Co Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Eisai R & d Management Co Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###